Main Text
Regulatory RNAs are increasingly recognized as a new class of drug targets for treating infectious diseases, cancers, and genetic disorders 1 . RNAs are highly flexible macromolecules and their regulatory functions often require specific changes in their three-dimensional (3D) structure 2 .
Such structural dynamics can optimize interactions with proteins, provide a basis for RNA-based molecular switches, or allow one RNA to satisfy the distinct structural requirements of multi-step catalytic cycles 2 . Given the importance of structural dynamics to RNA function, it should not come as a surprise that certain aminoglycoside antibiotics act by impairing dynamics in ribosomal RNAs that is important for codon recognition 3 . Because this is one of few proven strategies for targeting RNA therapeutically, there is considerable interest in pursuing approaches for inhibiting RNA activity by interfering with, or exploiting, RNA structural dynamics 4, 5 .
Recently, regulatory RNAs have been shown to transiently morph into non-native secondary structures, termed 'excited states' (ESs), by reshuffling base pairs (bps) in and around non-canonical motifs such as bulges and apical loops [6] [7] [8] [9] [10] [11] . Despite their low abundance, ESs have been shown in some instances to play functional roles as intermediates during folding or regulation 6, 9, 10 . Among the many conformations sampled by a given RNA, ESs are unique in that they represent the most stable conformations that have lost key characteristics of the native ground state (GS) secondary structure typically required for normal function. They therefore represent an interesting class of conformational states that, if stabilized with a therapeutic agent, could lead to potent inhibition of RNA cellular activity. For example, this could provide a means by which to inhibit RNA-protein interactions by disrupting the RNA structural elements recognized by proteins. However, it has yet to be shown for any RNA that its non-native excited-state does not support cellular activity as is expected for functions that critically depend on RNA secondary structure (Fig 1a) . It also remains unclear whether these non-native conformations form readily within the cellular environment as observed in vitro (Fig   1a) . The cellular environment could energetically bias the ensemble toward the native GS making it more difficult to stabilize the ES through interactions with a therapeutic agent in vivo compared to in vitro.
To address the stability and biological activity of ESs in vivo, we developed a stabilize-andrescue approach that uses point substitution mutations to invert the equilibrium so that the ES becomes the dominant (>50% population) conformation and secondary rescue mutations to restore the GS conformation and control for sequence effects (Fig 1a) . The mutations are chosen to minimally interfere with structural features of the GS known to be important for function. The degree to which a given mutation stabilizes the ES relative to the GS is measured in vitro using Nuclear
Magnetic Resonance (NMR) spectroscopy. We then examine the degree to which increasing the population of the ES at the expense of the GS leads to a corresponding decrease in cellular activity (Fig 1a) . If an ES forms in cells with abundances comparable to those measured in vitro, and if the ES conformation does not support cellular activity, mutations stabilizing the ES should inhibit cellular activity to a degree commensurate with the degree to which they decrease the GS population in vitro (Fig 1b) . This in turn would imply that ESs are viable cellular drug targets. If, on the other hand, the cellular environment preferentially biases the ensemble away from the ES in favor of the GS, and/or if the ES supports cellular activity, the impact of the mutations on activity would be attenuated in cells (Fig 1b) . This would in turn imply that the ES is not a viable drug target.
We applied the above stabilize-and-rescue approach (Fig 1) to two regulatory RNAs in the HIV-1 virus, trans-activation response element (TAR) (Fig 2a) and Rev response element (RRE) (Fig   2b) . The structure of these highly conserved RNAs has previously been shown to be critical for viral functions that involve binding to viral and host proteins [12] [13] [14] [15] [16] [17] [18] [19] [20] . In both cases, the ES remodels key structural features in the native GS required for protein recognition [6] [7] [8] .
HIV-1 TAR is located at the 5' end of the viral genome and promotes transcription elongation by binding to the viral protein Tat and human super elongation complex (SEC). This interaction is required to release RNA polymerase II from promoter-proximal pausing, allowing for efficient transcription of the viral genome 21 . The TAR GS structure has been shown to be critical for its biological activity and Tat and SEC form extensive interactions with the TAR bulge, upper stem, and apical loop 22, 23 . Prior studies showed that TAR adopts two non-native ESs, termed 'ES1' and 'ES2' (Fig 2a) 6,7 . ES1 involves conformational changes within the apical loop, which zip up the hairpin by sequestering nucleotides into two non-canonical bps (Fig 2a) 6 . On the other hand, ES2 remodels the entire secondary structure from the bulge motif to the apical loop, creating a 1-nucleotide bulge, a dinucleotide apical loop, and four non-canonical bps (Fig 2a) 7 . Because ES2 greatly remodels the TAR structure, it is highly unlikely to support transcriptional trans-activation. Therefore, mutations stabilizing ES2 are expected to significantly inhibit viral transcription unless the cellular environment substantially biases the equilibrium to favor the GS.
We designed a series of mutations that stabilize ES2 and corresponding secondary mutations that restore the GS conformation to control for effects arising purely due to changes in sequence (Fig 2c, Supplementary note 1 , and Supplementary Figs 1-3) . The degree to which a given mutation biases the ensemble toward the GS or ES conformation was measured using NMR spectroscopy (see Methods, Fig 2c, Supplementary Fig 2) . The mutants were then tested in a Tatdependent HIV-1 LTR-driven luciferase reporter assay (Fig 3a-b) .
Based on NMR relaxation dispersion experiments 24 , TAR-G28U stabilizes ES2 to a population of ~99.8% (Fig 2c, Supplementary Fig 4, Supplementary Tables 1 and 2 ). The experiments indicate that TAR-G28U back-exchanges with a GS-like conformation that has an equilibrium population of ~0.2% ( Supplementary Fig 4 and Supplementary Tables 1 and 2 ). NMR analysis reveals that the TAR-G28U/C37A rescue mutation restores a GS-like conformation, although a small population for ES2 is likely given line broadening in NMR spectra (Fig 2c, Supplementary Fig 2a) . These results highlight how mutations do not induce all-or-nothing behavior (i.e. GS or ES) but rather redistribute the ensemble along a continuous scale (Fig 1) .
If TAR-G28U forms the ES2 conformation within cells with an abundance comparable to that measured in vitro, and if the TAR ES2 conformation is indeed inactive, we would expect the mutant to
show at least a 1000-fold reduction in activity relative to WT (an even greater level of inhibition is in principle possible if the exchange kinetics between the GS and ES are slow relative to protein binding). As positive controls, we first tested double mutants TAR-G36C/C29G and TAR-G28C/C37G, which adopt a predominantly GS-like conformation based on NMR (Fig 2c,   Supplementary Fig 2c) . As expected, the mutants did not have statistically different trans-activation activity relative to WT (two-way ANOVA, P > 0.05) (Fig 3b) . In contrast, the trans-activation activity of the ES2-stabilizing TAR-G28U mutant fell below detectable levels with indistinguishable activity from the -Tat negative control (two-sided unpaired Student's t-test, P > 0.05), corresponding to at least 100-fold decrease in activity (Fig 3b) . The activity increased significantly (two-way ANOVA, P < 0.05) and was restored to WT TAR levels (two-way ANOVA, P > 0.05) upon introduction of a second rescue mutation (TAR-G28U/C37A) (Fig 3b) . Although not statistically significant, the lower mean activity observed for TAR-G28U/C37A relative to WT could arise from incomplete restoration of the GS and/or because the sequence of the G28-C37 base pair is important for activity.
To test the robustness of these results, experiments were repeated for three other sets of mutants targeting different TAR residues (TAR-A27C, TAR-G36U, and TAR-U38A) and the results were similar to those obtained for TAR-G28U. All three ES2-stabilizing mutants drastically diminish TAR activity, while all but one GS-rescue mutation at least partially restores activity (two-way ANOVA, P < 0.05) (Fig 3b) . For most cases, the effect of the mutation on activity in vivo correlates with the degree of ES stabilization measured in vitro. For example, NMR spectra of TAR-G36U and TAR-A27C indicate that these mutants bias the conformational equilibrium toward ES2 to a similar extent as TAR-G28U (Fig 2c) , and correspondingly, their activity is indistinguishable from that observed for TAR-G28U (two-way Anova, P > 0.05) (Fig 3b) . While TAR-U38A also stabilizes ES2, NMR spectra indicate that the bias is not as strong as the other mutants (Fig 2c) . Correspondingly TAR-U38A has marginally higher activity (~6% of WT TAR) compared to other ES2-stabilizing mutants (Fig 3b) . Likewise, the partial rescue of TAR-G36U/C29A in the transactivation assay mirrors the partial conformational rescue as assessed by NMR (Fig 2c and Fig 3b) , although we cannot rule out that the identity of the closing G36-C29 bp is also important for protein recognition (Fig 2c and Fig 3b) . While the TAR-U38A/A27U and TAR-A27C/U38G mutants only partially restore activity despite NMR spectra showing a strong bias toward the GS, this is not surprising given that the mutations disrupt an U23•U38-A27 base triple known to be important for Tat binding (Fig 2c and Fig   3b ) 25, 26 . Taken together, the agreement between the conformations determined in vitro by NMR and the cell-based trans-activation activity suggests that the energetic stability of ES2 relative to the GS are not substantially altered in the cell relative to the in vitro environment. The results also confirm that the ES2 conformation is inhibitory, as is expected given prior studies showing the importance of the TAR GS secondary structure for transactivation [12] [13] [14] [15] [16] 22 .
TAR ES1 does not change the secondary structure as significantly as ES2, and two ES1-stabilizing mutants 6 (TAR-C30U and TAR-A35G) does not significantly decrease trans-activation relative to WT activity (two-way ANOVA, P > 0.5) (Fig 3b) . Therefore, stabilizing ES1 is unlikely to represent a favorable therapeutic strategy.
RRE RNA mediates nuclear export of incompletely spliced viral RNAs by cooperatively binding multiple copies of the viral Rev protein 17 . This assembly is initiated through binding of Rev to the purine rich region of RRE stem IIB 17 . Our recent work 8 showed that RRE stem IIB forms two nonnative ESs (ES1 and ES2) both of which disrupt key structural elements recognized by Rev, including the G47-A73 and G48-G71 mismatches and U72 bulge (Fig 2b) . ES1 reshuffles the lower bulge while ES2 remodels both the lower and upper bulge (Fig 2b) 8 .
As was done for TAR, point substitution mutations stabilizing the RRE ESs and corresponding rescue mutations that restore the GS were designed and verified using NMR (Fig 2c, Supplementary note 2, Supplementary Figs 5-6) . The mutants were then tested in an RRE-dependent RNA export assay to monitor RRE activity (Fig 3c-d) . Due to the localized nature of the conformational change, it was challenging to design mutants that stabilize the RRE ESs to >99% population. Rather, extreme broadening of the NMR spectra indicate that RRE-A68C only partially stabilizes ES2 to a population ranging between 20% and 80%. The GS conformation is largely rescued by RRE-A68C/G50A/C69U
based on the restoration of WT chemical shifts. As expected since it only partially stabilizes the ES, RRE-A68C showed only a 2-fold reduction in RRE-mediated export relative to WT while the rescue mutant RRE-A68C/G50A/C69U restores activity to within ~80% of WT (Fig 3d) . Likewise, RRE-U72C partially stabilizes the cumulative ES1 + ES2 population to 20%-80%, and decreases export activity to ~70% of WT, while the rescue mutant RRE-U72C/G48A/G71A restores activity to ~100% of WT.
Another double mutant, RRE-A68C/U72C, which also partially stabilizes ES2 to 20%-80% based on NMR, also shows a 2-fold reduction in RRE-mediated export to ~50% of WT while the rescue mutant RRE-U72C/G48A/G71A/A68C/G50A/C69U restores activity to ~70% of WT (Fig 3c) . Similar results were also observed for Rev-RRE binding in cells using a previously described TAR-RRE hybrid transactivation assay 27 ( Supplementary Fig 7) , confirming that inhibition of RRE export is indeed due to inhibition of Rev-RRE binding.
Although the effects are smaller than those observed for TAR, the robust correlation between the impact on conformation and on RRE activity for different ES-stabilizing and rescue mutants indicates that stabilizing the RRE ES conformation is indeed inhibitory (Fig 3d and Supplementary   Figs 5-7 ). Since the mutants only stabilize the RRE ES to ~50% population, the 2-fold reduction in activity is consistent with the ES conformation being fully inhibitory and the observed remaining activity can be attributed to a residual GS population. Once again, if the cellular environment preferentially stabilizes the GS relative to the ES, we would have expected the mutations to have a smaller effect within cells than predicted from their equilibrium populations, which is not observed.
The results presented here indicate that stabilizing non-native RNA ESs could be a viable strategy for inhibiting RNA-protein interactions and cellular activity. For two RNAs, the cellular environment does not seem to significantly alter the energetic stabilities of the ES relative to the GS compared to in vitro conditions. Because the ES stabilize-and-rescue approach presented here maximally changes RNA structure while minimally impacting sequence, it provides a powerful approach by which to test the structure-dependence of RNA function within cells.
Online Methods

RNA sample preparation
Unlabeled RNA samples (TAR-G28U, TAR-G28U/C37A, TAR-G36U, TAR-G36U/C29A, TAR-U38A, TAR-U38A/A27U, TAR-A27C, TAR-A27C/U38G , WT TAR, and uucgES2TAR) were prepared using a MerMade 6 DNA/RNA synthesizer (BioAutomation) for solid-phase oligonucleotide synthesis using standard phosphoramidite RNA chemistry and deprotection protocols. 13 C/ 15 N labeled RNA samples (RRE-A68C/G50A/C69U/U72C/G48A/G71A, RRE-A68C/U72C, RRE-U72C/G48A/G71A, RRE-U72C, RRE-A68C/G50A/C69U, RRE-A68C and TAR-G28U) used for NMR characterization were prepared by in vitro synthesis using T7 RNA polymerase (New England BioLabs), DNA template (Integrated DNA Technologies) containing the T7 promoter, and uniformly labeled 13 
NMR spectroscopy
Assessing impact of mutations using chemical shift mapping experiments
The impact of the mutations on RNA structure was initially assessed by recording 1D 30 .
TAR:
Comparison of NMR spectra for each TAR mutant with corresponding spectra of WT TAR and a validated TAR ES2 mutant (uucgES2 TAR) 31, 32 was used to assess the degree of ES-versus GSstabilization. Although the entire spectrum was evaluated ( Supplementary Fig 2) , key residues used in this analysis include A22 C8-H8/C2-H2, U23 C6-H6, C24 C6-H6, A35 C8-H8, U40 C6-H6, and C41
C6-H6. To determine the degree of stabilization of ES-and GS-stabilizing mutants, the extent of broadening for these spectra was investigated. The broadening of TAR-U38A is apparent in many resonances, but particularly in the peak tentatively assigned to U23, which is not broadened out in the other ES2 traps. The broadening of TAR-G28U/C37A and TAR-G36U/C29A relative to the other rescue mutants is also particularly visible in U23.
RRE: Likewise, comparison of NMR spectra for each RRE mutant with corresponding spectra of WT RRE was used to assess the degree ES-versus GS-stabilization. The entire spectra were evaluated ( Supplementary Fig 5) , and the key resonances used in this analysis include A68 C8-H8, U72 C6-H6, G47 C8-H8, G48 C8-H8, and G71 C8-H8. The broadening of these resonances, which experience significant changes in chemical shift between the GS and ESs were used to estimate the relative stability of ESs versus GS.
N R 1ρ relaxation dispersion
15 N R 1ρ relaxation dispersion (RD) NMR experiments were carried out using a 700 MHz Bruker Avance III spectrometer equipped with an HCN cryogenic probe. Measurements were carried out at 25°C on the 0.7 mM uniformly 13 C/ 15 N-labeled TAR-G28U sample. R 1ρ RD for N3 spins were measured using a 1D acquisition scheme 33 using spinlock powers (ω2π -1 Hz) and offsets (Ω2π -1 Hz)
listed in Supplementary Table 1 and using 7 time delay points between 0 and 120 ms. For each delay time point, peak intensities were obtained using NMRPipe and R 1ρ values were calculated by fitting to a monoexponential decay function using an in-house python script 34 . Errors in R 1ρ were estimated using Monte Carlo simulations with 500 iterations as previously described 35 . The RD data was analyzed to obtain exchange parameters through numerical solutions of the Bloch-McConnell equations 36 using an in-house python script 37 . As expected the TAR-U42-N3 negative control showed no dispersion. The TAR-U38-N3 data was fit with an individual two-state model using ground state effective field alignment. Model selection was preformed as previously described 37 using the Akaike's (wAIC) and Bayesian information criterion (wBIC) weights to select the model with the highest relative probability 38, 39 .
Plasmid construction
The Tat and Rev expression plasmids, pcTat 27 and pcRev 40 , pcTat/Rev 27 , and pBC12-CMV 27 have been described previously. The Renilla luciferase (RLuc) internal control was generated by PCR amplification of the RLuc ORF, which was then cloned into pcDNA3 (Invitrogen) using unique HindIII and XhoI restriction sites. The Firefly luciferase (FLuc) reporter plasmids with TAR and RRE, both wild-type and mutants, were constructed as follows. The pFLuc-TAR plasmid was generated by cloning the FLuc gene into pcDNA3 (Invitrogen) using NotI and XhoI restriction sites to generate pcDNA-FLuc. The HIV-LTR was next cloned as a Bam HI/Hind III fragment into pcDNA-FLuc digested with Bgl II and Hind III, which removes the entire CMV promoter. TAR mutants were introduced at Bgl II and Hind III restriction sites using annealed DNA oligos (IDT) that were designed to have overhangs complimentary to Bgl II and Hind III. The pFLuc-TAR/RRE plasmid was generated with the same Bgl II and Hind III restriction sites using annealed DNA oligos (IDT) containing RRE stem II sequence (66nt). The pFLuc-RRE was derived from pDM128-PL 41 . The CAT gene was replaced with the FLuc gene using Sal I and Bgl II restriction sites (pMP-1). The RRE and variants were generated by ligating in the whole RRE (~350 nt) inserts amplified using two-step recombinant PCR, using the HIV-1 proviral clone pNL4-3 as the template, (AIDS reagent cat #114). The PCR products of RRE and variants were then inserted to pMP-1 at Kpn I/Xba I restriction sites.
Trans-activation assays
HeLa cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamycin at 37 °C and 5% CO 2 . Cells were plated to 3 X Fig 7) .
RRE-mediated RNA export assay
293T cells were maintained in DMEM supplemented with 10% FBS and 0.1% gentamycin at 37 °C and 5% CO 2 . Cells were plated to 2 X10 5 cells per well in 12-well plates and transfected using PEI with 5 ng pFLuc-RRE reporter plasmid, 5 ng RLuc internal control, 1 ng pcRev, and pBC12-CMV
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filler DNA up to 1010 ng total DNA. Media was replaced at 24 h post-transfection and cells were lysed at 48 h post-transfection using 200 µl passive lysis buffer (Promega). FLuc and RLuc activity was measured using a dual-luciferase reporter assay system (Promega). Reported values are the quotient of FLuc activity and RLuc activity with values normalized to WT RREII activity for every replicate (Fig   3d) .
Statistical analysis
Statistical analysis was done using the program JMP (JMP Pro, Version 14, SAS Institute Inc., Cary, NC, 1989-2019). The data was not normalized to WT TAR for the trans-activation assay because there was not a significant systematic effect of replicate on the data. For both RRE assays, the data was normalized to WT RREII because there was a significant systematic effect of replicate on the data. For all three assays, the FLuc/RLuc quotient was log transformed for statistical analysis.
A two-sided unpaired Student's t-test was used to compare the +Tat and -Tat distributions for the trans-activation assays and a two-sided ANOVA was used to compare the difference between distributions (+Tat and -Tat; +Rev and -Rev; or +Tat/Rev and +Tat) for different samples for all three assays. after log-transformation of the data; *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided ANOVA). 
